menu search

SIOX / Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge

Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
Sio Gene Therapies Inc (NASDAQ: SIOX) will terminate its licensing agreement with the University of Massachusetts to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM2, for GM1 gangliosidosis and GM2 gangliosidosis, respectively. In. Read More
Posted: Apr 28 2022, 09:06
Author Name: Benzinga
Views: 111060

SIOX News  

Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge

By Benzinga
April 28, 2022

Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge

Sio Gene Therapies Inc (NASDAQ: SIOX) will terminate its licensing agreement with the University of Massachusetts to develop and commercialize gene more_horizontal

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

By GlobeNewsWire
February 2, 2022

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing more_horizontal

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

By GlobeNewsWire
February 2, 2022

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing more_horizontal

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

By GlobeNewsWire
February 2, 2022

Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing more_horizontal

Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

By Benzinga
February 1, 2022

Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy more_horizontal

Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

By Benzinga
February 1, 2022

Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy more_horizontal

Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

By Benzinga
February 1, 2022

Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy more_horizontal

3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now

By PennyStocks
October 5, 2021

3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now

Are these 'must watch' penny stocks on your list right now? The post 3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now appeared first on Penn more_horizontal


Search within

Pages Search Results: